atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

Stock Information for ATAI Life Sciences N.V.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ATAI Life Sciences N.V.

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
atai Life Sciences Announces $50 Million Private Placement Financing
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders
HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Atai Life Sciences N.V. (NASDAQ: ATAI)
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.